Literature DB >> 1731582

Lung-restricted activation of the alveolar macrophage/monocyte system in pulmonary sarcoidosis.

J Müller-Quernheim1, S Pfeifer, D Männel, J Strausz, R Ferlinz.   

Abstract

An activation of T-cells that is restricted to the lung has been demonstrated in pulmonary sarcoidosis. The role of blood monocytes (MO) and alveolar macrophages (AM) in this concept of compartmentalized inflammation has not yet been evaluated. In order to elucidate this question, we measured the release of tumor necrosis factor alpha (TNF alpha) and interleukin-1 (IL-1) by peripheral blood mononuclear cells (PBMNC) and AM in 43 patients with sarcoidosis (32 with active, 11 with inactive disease) without therapy and correlated the spontaneous monokine release to parameters of the T-cell alveolitis and the course of the disease. TNF alpha as well as IL-1 were spontaneously released by AM of the active group, i.e., 2,385 +/- 735 pg/ml/10(8) cells/24 h and 7/12 (IL-1+/total), respectively. Autologous PBMNC were quiescent, releasing only baseline levels of any monokine. AM were not activated in the inactive group, releasing 500 +/- 212 pg/ml/10(6) cells/24 h TNF alpha, whereas 1/5 were IL-1-positive (p less than 0.05 in both comparisons), which is within the range of the control group. Kinetic experiments revealed that the TNF alpha gene of AM is activated in vivo, resulting in TNF alpha mRNA-positive, TNF alpha-releasing cells that, cultured in vitro, regulate the TNF alpha gene transcription down and cease to release TNF alpha. Interestingly, there is no stringent correlation between the spontaneous release of TNF alpha by AM and signs of T-cell activation as soluble interleukin-2 (IL-2) receptor serum concentration, release of IL-2, and expression of IL-2 receptor by alveolar T-cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731582     DOI: 10.1164/ajrccm/145.1.187

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  24 in total

1.  Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells.

Authors:  A Prasse; C G Georges; H Biller; H Hamm; H Matthys; W Luttmann; J C Virchow
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 2.  Neurosarcoidosis.

Authors:  Dakshinamurty Gullapalli; Lawrence H Phillips
Journal:  Curr Neurol Neurosci Rep       Date:  2004-11       Impact factor: 5.081

3.  Role of genetic polymorphisms in ACE and TNF-alpha gene in sarcoidosis: a meta-analysis.

Authors:  Igor Medica; Andrej Kastrin; Ales Maver; Borut Peterlin
Journal:  J Hum Genet       Date:  2007-09-04       Impact factor: 3.172

4.  Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis.

Authors:  I Bäumer; G Zissel; M Schlaak; J Müller-Quernheim
Journal:  Lung       Date:  1997       Impact factor: 2.584

5.  Modulation of IL-1 beta, IL-6, IL-8, TNF-alpha, and TGF-beta secretions by alveolar macrophages under NO2 exposure.

Authors:  K Kienast; M Knorst; J Müller-Quernheim; R Ferlinz
Journal:  Lung       Date:  1996       Impact factor: 2.584

6.  Inter-relationship between tumour necrosis factor-alpha (TNF-alpha) and TNF soluble receptors in pulmonary sarcoidosis.

Authors:  L Armstrong; N M Foley; A B Millar
Journal:  Thorax       Date:  1999-06       Impact factor: 9.139

7.  Expression of thioredoxin in granulomas of sarcoidosis: possible role in the development of T lymphocyte activation.

Authors:  T Koura; Y Gon; S Hashimoto; A Azuma; S Kudoh; Y Fukuda; I Sugawara; J Yodoi; T Horie
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

8.  Association between sarcoidosis and lymphoma revisited.

Authors:  M Karakantza; E Matutes; K MacLennan; N T O'Connor; P C Srivastava; D Catovsky
Journal:  J Clin Pathol       Date:  1996-03       Impact factor: 3.411

9.  Alveolar macrophages from bronchoalveolar lavage of patients with pulmonary histiocytosis X: determination of phenotypic and functional changes.

Authors:  M Uebelhoer; B Bewig; K Sternberg; K Rabe; D Nowak; H Magnussen; J Barth
Journal:  Lung       Date:  1995       Impact factor: 2.584

10.  Dramatic response to infliximab in refractory neurosarcoidosis.

Authors:  Sreekanth Chintamaneni; Aarat M Patel; Samuel B Pegram; Hirenkumar Patel; Heidi Roppelt
Journal:  Ann Indian Acad Neurol       Date:  2010-07       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.